April 24, 2014—The nation’s No. 1 and 2 producers of intravenous immune globulin, together with the Plasma Protein Therapeutics Association, are paying a combined $128 million to settle charges that they conspired to fix the prices of IVIG and the blood plasma derivative albumin that the companies sold directly to hospitals and other buyers between 2003 and 2009.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)